News on Medial

IXP unveils Rs 200 Cr early-stage fund for lifesciences startups

EntrackrEntrackr · 1y ago
IXP unveils Rs 200 Cr early-stage fund for lifesciences startups
Medial

IXP, a Life Sciences VC backed by JV Ventures, has announced the launch of its first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from pre-seed to Series A stages. The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 200 crore, with a greenshoe option of Rs 100 crore. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Life Sciences sector, the fund will invest in innovations across areas such as pharma, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals. Through IXP Venture Studio, it will co-create companies alongside scientists to develop ideas that address unmet market needs. Unlike traditional VCs, it takes a hands-on approach, actively participating from concept to scale. The Venturepreneur Program has been designed to transform scientists into founders. According to IXP, early-stage companies require access to larger ecosystems, including laboratories, networks, and R&D services, which it provides through PoweRx, the Life Sciences vertical of JV Ventures. The VC firm leverages synergies within the group to create a winning proposition for portfolio companies. IXP (Innovation Acceleration Platform) aims to support scientists and innovators in their entrepreneurial journey by integrating them into a rich life sciences ecosystem. The VC firm emphasizes that it is built by a strong team and understands the capital-intensive nature and long gestation periods associated with R&D, helping bring innovative ideas to market.

Related News

IIFL Fintech floats Rs 500 Cr Fund II

EntrackrEntrackr · 1m ago
IIFL Fintech floats Rs 500 Cr Fund II
Medial

IIFL Group backed IIFL Fintech Fund has announced the final close of its second fund after raising Rs 500 crore from domestic family offices and high net worth individuals. The Series II fund targets early to growth stage fintech startups, with a focus on companies using generative artificial intelligence to build financial services products. The fund plans to invest in 20 to 25 startups across lending, payments, compliance, wealthtech, insurtech, and embedded finance. Around 20 to 25 percent of the second fund will be allocated for follow on investments in top performing companies from its first fund. IIFL Fintech had announced the first close of its second fund at Rs 200 crore in January 2025 and has already backed five startups through this. These include companies such as education focused fintech GrayQuest, voice AI startup Fundamento, banking infrastructure startup Knight Fintech, and a secondary share purchase in document infrastructure firm Leegality, among others. According to IIFL Fintech, it actively partners with fintech founders to help them validate, deploy, and scale their solutions within a large financial services ecosystem. The fund closed its first fund in 2022 after raising Rs 200 crore. IIFL Fintech Fund was set up in 2021 with the aim of investing in early stage fintechs that the IIFL Group could collaborate with. Over the last four years, the IIFL Fintech Fund has invested across multiple fintech segments. Its portfolio includes Leegality, FinBox, DataSutram, Finarkein Analytics, Finvu, Trendlyne, Insurance Samadhan, Xtracap Finance, Castler, Vitra.ai, EasyRewardz, Multipl, Riskcovry, and TrustCheckr, which was sold to Truecaller.

Download the medial app to read full posts, comements and news.